Greetings and welcome to the IsoRay First Quarter Fiscal Year 2019 Earnings Conference Call. [Operator Instructions]. I now would like to turn the conference over to your host, Mark Levin. Thank you. You may begin.

Thank you, Operator. Good afternoon and thank you for joining us today for the IsoRay Fiscal First Quarter 2019 Earnings Call for the quarter ended September 30, 2018. Before we get started, I will take a few minutes to read the forward-looking statements. Certain statements in this conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. When used in this conference call words such as, will, believe, expect, anticipate, encourage, and similar expressions as they relate to the company or its management as well as assumptions made by and information currently available to the company’s management identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and beliefs about future events. As with any projection or forecast they are inherently susceptible to uncertainty and changes in circumstances and the company undertakes no obligation to and expressly disclaims any obligation to update or alter its forward-looking statements whether resulting from such changes, new information, subsequent events or otherwise. Additional information concerning forward-looking statements is contained under the headings of Safe Harbor Statement and Risk Factors listed from time to time in the company’s filings with the Securities and Exchange Commission. Statements made on today’s call are as of today, November 08, 2018. Momentarily, I will turn the call over to IsoRay’s Interim CEO, Lori Woods, who will review the first quarter financial results. Following her prepared remarks, we will take questions from our analysts and institutional investors. I will now turn the call over to Lori Woods.

Thank you, Mark. Welcome everyone to IsoRay's fiscal first quarter 2019 earnings conference call for the quarter ending September 30, 2018. We anticipate that our Form 10-Q will be filed with the SEC on or around November 9th. I will begin our call with an overview of our financial results and then I will give some updates on the previously mentioned product launches as well as takeaways from our recent participation in ASTRO 60th Annual Meeting that took place in San Antonio, Texas. Revenue for the first quarter ended September 30th grew 29% to 1.56 million versus 1.21 million for the same period last year, this was the sixth consecutive quarter of year over year double digit revenue growth. First quarter revenue was comprised of 88% for prostate brachytherapy with the balance or 12% of revenue attributed to other brachytherapy that includes brain, lung, head and neck and gynaecological. Gross profit as a percentage of revenues for the first quarter ended September 30, 2018 increased to 33.5% compared to 21.9% for the quarter ended September 30, 2017. The gross margin increase was primarily driven by our success in improving our system for the utilization of isotope in the support of our sales growth. First quarter gross profit dollars of 524,000 nearly doubled when compared to the same period last year. Total operating expenses consisting of sales and marketing, general and administrative and research and development were $2.04 million in the quarter versus $1.82 million in fiscal first quarter 2018. Total R&D expense increased 16% versus the comparable prior year quarter to 420,000 due to increases in proprietary R&D primarily related to the recent launch of the Blu Build delivery system. This increase was partially offset by 65% decline in collaborative R&D expenses primarily related to the development of GammaTile Therapy.…

[Operator Instructions]. Our first question comes from Ed Woo with Ascendant Capital. Please proceed with your question.

My question is on GammaTile, you mentioned that the launch will be expected summer of 2019. How confident are you that GT Medical will be able to hit that and what is your role involved with the launch or is it mainly GT Medical that will be formulating the plan and launching the product?

A little clarity, we are planning along with the GT Medical Technologies to actually treat the first patient this month. They then expect a limited market relief over the next couple of quarters working towards a more broadly based commercial launch sometime next year. So I'm sorry can you repeat the second part of that question?

Yes what is your role to assist GT Medical? Is it very involved in terms of investments or is it pretty much just provide the product. So we are providing product, we have a manufacturing agreement with them. We will be supporting them in any way we can be helpful but this is their product launch with their sales group and we will be there to support and to provide product.

Are you involved with any of their marketing budgets? Is there any type of co-investing?

We are not involved in their marketing at this point in time nor their sales.

And then it's good to see that you guys had pretty good meetings at the various conferences, is there any update or should we expect any type of clinical data or research coming out with the next you know pretty soon time period?

It's hard for me to be able to answer that question only from the perspective that we don't have control of that. I know there are doctors out there that are actively involved in research of Cesium-131 but when they get published it is completely out of our hands and so what I will say is when those things happen we will definitely be communicating with you.

[Operator Instructions]. There are no further questions at this time. At this point I'd like to turn the call back to Lori Woods for closing comments.

Thank you everyone for your interest in IsoRay and for joining our conference call. We look forward to speaking with you soon.